Nuclea Tech, Boston Medical Center Partner on Cancer Gene Expression Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nuclea Technologies today announced a deal with Boston Medical Center for the discovery of new gene expression biomarkers to diagnose cancer.

Under the partnership, research will be directed at gene expression in specific tumors to help radiologists "review results in a different and more comprehensive way," Nuclea said in a statement.

Based in Pittsfield, Mass., Nuclea discovers and develops genetic, protein, and antibody biomarkers and diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.